What are the appropriate sites for obtaining microbiology specimens to detect multidrug‑resistant organisms in hospitalized patients?

Appropriate Sites for Microbiology Specimens to Detect Multidrug-Resistant Organisms in Hospitalized Patients

For detecting multidrug-resistant organisms (MDROs) in hospitalized patients, obtain specimens from both clinical diagnostic sites (blood, surgical wounds, protected respiratory samples) and screening sites (rectal swabs, nasal swabs, and groin swabs), with rectal swabs being the highest-yield screening site for most intestinal MDROs. 1

Clinical Diagnostic Specimens vs. Screening Specimens

The European guidelines clearly distinguish between two fundamentally different specimen types 1:

Clinical Diagnostic Specimens

These are obtained to diagnose active infections and should be prioritized for:

• Blood cultures - highest priority for severe infections and bacteremia
• Surgical wound specimens - from deep tissue after debridement
• Protected respiratory specimens - bronchial brush, protected distal specimens, bronchoalveolar lavage
• Sterile body fluids - cerebrospinal fluid, pleural fluid, joint fluid, peritoneal fluid
• Urine - particularly noting catheter status

These specimens are linked to severe infection and directly impact mortality and morbidity 1.

Screening Specimens for Colonization

These detect asymptomatic carriers and prevent transmission:

• Rectal swabs or stool - most frequent and highest-yield screening site
• Nasal/rhinopharynx - primarily for MRSA detection
• Groin/inguinal area - alternative to rectal, particularly valuable for Candida auris
• Skin and vagina - for specific targeted surveillance 1

Pathogen-Specific Optimal Screening Sites

Recent high-quality research provides critical pathogen-specific guidance:

Rectal Swabs (Highest Overall Yield)

• 95.8% detection rate for Klebsiella pneumoniae 2
• 100% detection rate for vancomycin-resistant enterococci (VRE) 2
• 66.7% detection rate for Pseudomonas aeruginosa 2
• Optimal for ESBL-producing and carbapenem-resistant Enterobacterales 3, 4

Groin/Inguinal Swabs

• 88.9% of Candida auris detected exclusively from groin swabs 2
• Sensitivity of 91.8% and specificity of 88.7% compared to rectal swabs for intestinal MDROs 5
• Less embarrassing for patients, more acceptable alternative 5
• Higher colony counts than rectal swabs in some cases 5

Nasal Swabs

• Primary site for MRSA detection 6, 4
• Rarely detects other MDROs 4
• Should be combined with rectal/groin screening for comprehensive surveillance

Wound and Risk-Based Sites

• Wounds - more sensitive for nonfermenting gram-negative organisms 3
• Tracheal secretions - for ventilated patients
• Urine - for catheterized patients 3

Critical Pitfalls to Avoid

Do not rely on a single screening site. Rectal screening alone would miss nearly 90% of Candida auris carriers, while groin-only screening would fail to detect most K. pneumoniae and all VRE carriers 2. The evidence strongly supports multi-site screening for comprehensive MDRO detection.

Do not swab wounds without proper preparation. For infected wounds requiring culture, cleanse and debride first, then obtain deep tissue specimens by curettage or biopsy rather than superficial swabs 7. Superficial swabs provide less accurate results and may miss the true pathogen.

Do not mix screening and diagnostic specimens in surveillance data. These serve different purposes and must be classified separately 1. Screening specimens cannot be used to calculate resistance rates within a species but can monitor carriage prevalence.

Practical Implementation Algorithm

For high-risk hospitalized patients (ICU, oncology, transplant, prolonged hospitalization >5-7 days, recent hospitalization abroad, recent broad-spectrum antibiotic use):

1. On admission or within 48 hours:

   • Rectal swab (or groin as alternative)
   • Nasal swab
   • Groin swab if Candida auris is endemic
   • Risk-based sites: wounds, urine if catheterized, tracheal secretions if ventilated 6, 3, 8

2. During hospitalization:

   • Repeat screening on day 5, then weekly until discharge 8, 9
   • Clinical diagnostic specimens as indicated by infection signs

3. Stratify by hospital unit type - ICUs, transplant units, and hematology/oncology units require more intensive surveillance 1

Timing Considerations

Obtain specimens before initiating antibiotic therapy whenever possible 7. For hospitalized patients, document the interval between admission and sampling to distinguish nosocomial (>48 hours) from community-acquired infections 1. This timing is critical for accurate epidemiological surveillance and infection control program evaluation 1.

The evidence demonstrates that MDRO colonization prevalence increases dramatically during hospitalization - from baseline rates of 52.2% for ESBL to 71.7% after 3 weeks, and from 4.7% to 18.9% for carbapenem-resistant Acinetobacter 8. This underscores the importance of both admission and serial screening.